QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: GVP Module VI Special Situations and ICSR Reporting

Test your understanding of the concepts covered by GVP Module VI: Special Situations and ICSR Reporting.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A product-quality complaint describes a defective dosage form and a patient reaction. What is the most appropriate organisational response?

Keep the information solely within product quality until the investigation is complete Have pharmacovigilance assess the clinical information while the quality investigation proceeds and information is exchanged Send the complaint to pharmacovigilance only if the defect is confirmed Close the quality complaint because the reaction makes it an exclusively pharmacovigilance matter

Question 2 of 10 Which information is particularly important when assessing a breastfeeding exposure?

Only the mother's treatment start date Only whether the medicine was prescribed within the authorised indication Maternal exposure and treatment, breastfeeding status, infant exposure where known, and any effects in the infant The infant's outcome without recording the maternal medicinal-product exposure

Question 3 of 10 What is the primary benefit of controlled coding of special situations?

It eliminates the need for narrative case assessment It supports consistent classification and downstream analysis across cases and organisations It allows causality to be inferred from the coded circumstance It ensures every coded situation becomes an ICSR

Question 4 of 10 Which statement best distinguishes an overdose from its clinical consequences?

An overdose is itself proof of an adverse reaction The exposure circumstance and any resulting clinical event should be assessed separately An overdose is reportable only when it was intentional A clinical outcome need not be documented if the excessive exposure is clear

Question 5 of 10 What is the principal reason pregnancy-exposure information may require follow-up even when no adverse reaction is initially reported?

Pregnancy exposure always indicates a congenital anomaly The pregnancy or infant outcome may not be known at the time of the initial report Follow-up is required only to confirm product causality Pregnancy exposure information is never relevant until an adverse reaction is reported

Question 6 of 10 Why can occupational exposure be relevant to pharmacovigilance even when the exposed person was not receiving treatment?

Only treated patients can experience medicinal-product effects Occupational exposure can involve an individual and may be associated with clinical effects requiring assessment Occupational exposure is automatically classified as product misuse Occupational exposure belongs exclusively to occupational health and never to pharmacovigilance

Question 7 of 10 A patient uses a medicine outside its authorised indication and develops a suspected adverse reaction. Which processing approach is best?

Treat the off-label use as proof that the medicine caused the reaction Ignore the indication because only the reaction matters Capture the indication, exposure circumstances, and reaction, while assessing causality separately Reject the information because off-label use cannot generate an ICSR

Question 8 of 10 A mature special-situations process is best characterised by which combination of controls?

Automatic ICSR creation, minimal follow-up, and reliance on individual processor judgement Clear definitions, controlled intake, appropriate assessment, accurate coding, risk-based follow-up, cross-functional interfaces, metrics, and QPPV oversight Separate quality and pharmacovigilance systems with no information exchange Focus on case counts while excluding classification consistency from quality oversight

Question 9 of 10 A report states that a medicine 'did not work.' What should determine the pharmacovigilance assessment?

The phrase alone, because all lack-of-efficacy reports have the same significance Whether the medicine was prescribed by a specialist The product, indication, intended effect, clinical circumstances, treatment duration, disease severity, and consequences Whether the reporter used the term 'adverse reaction'

Question 10 of 10 Which metric is most useful for identifying a systemic weakness rather than merely counting case volume?

Total number of all safety reports received Number of medicinal products in the portfolio Recurring interface discrepancies and classification errors, analysed with processing and follow-up performance Number of employees in the pharmacovigilance department

Knowledge Assessment: GVP Module VI Special Situations and ICSR Reporting

Cookie Settings